Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
CYTR's Cash to Debt is ranked higher than
96% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. CYTR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CYTR' s 10-Year Cash to Debt Range
Min: 2.95  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
CYTR's Interest Coverage is ranked higher than
93% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYTR' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -4.58
M-Score: 2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -56043.00
CYTR's Operating margin (%) is ranked lower than
98% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. CYTR: -56043.00 )
Ranked among companies with meaningful Operating margin (%) only.
CYTR' s 10-Year Operating margin (%) Range
Min: -49606  Med: -731.50 Max: -21.16
Current: -56043
-49606
-21.16
Net-margin (%) -48275.00
CYTR's Net-margin (%) is ranked lower than
97% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. CYTR: -48275.00 )
Ranked among companies with meaningful Net-margin (%) only.
CYTR' s 10-Year Net-margin (%) Range
Min: -30118  Med: -683.33 Max: 408
Current: -48275
-30118
408
ROE (%) -74.65
CYTR's ROE (%) is ranked lower than
73% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CYTR: -74.65 )
Ranked among companies with meaningful ROE (%) only.
CYTR' s 10-Year ROE (%) Range
Min: -342.91  Med: -76.66 Max: 1.39
Current: -74.65
-342.91
1.39
ROA (%) -56.86
CYTR's ROA (%) is ranked lower than
71% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. CYTR: -56.86 )
Ranked among companies with meaningful ROA (%) only.
CYTR' s 10-Year ROA (%) Range
Min: -201.4  Med: -46.01 Max: 1.13
Current: -56.86
-201.4
1.13
ROC (Joel Greenblatt) (%) -7255.70
CYTR's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. CYTR: -7255.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12894.39  Med: -1280.61 Max: -45.66
Current: -7255.7
-12894.39
-45.66
Revenue Growth (3Y)(%) -100.00
CYTR's Revenue Growth (3Y)(%) is ranked lower than
91% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CYTR: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100  Med: -4.30 Max: 188.4
Current: -100
-100
188.4
EBITDA Growth (3Y)(%) -10.30
CYTR's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CYTR: -10.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.3  Med: -10.30 Max: 144.7
Current: -10.3
-67.3
144.7
EPS Growth (3Y)(%) -11.70
CYTR's EPS Growth (3Y)(%) is ranked lower than
56% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CYTR: -11.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTR' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3  Med: -11.70 Max: 94.8
Current: -11.7
-55.3
94.8
» CYTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CYTR Guru Trades in

Q4 2013

CYTR Guru Trades in Q4 2013

Steven Cohen 205,100 sh (New)
» More
Q1 2014

CYTR Guru Trades in Q1 2014

George Soros 81,800 sh (New)
Paul Tudor Jones 51,898 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

CYTR Guru Trades in Q2 2014

George Soros Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.20
CYTR's P/B is ranked higher than
61% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CYTR: 3.20 )
Ranked among companies with meaningful P/B only.
CYTR' s 10-Year P/B Range
Min: 1.24  Med: 3.80 Max: 64.65
Current: 3.2
1.24
64.65
P/S 1365.34
CYTR's P/S is ranked lower than
179% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. CYTR: 1365.34 )
Ranked among companies with meaningful P/S only.
CYTR' s 10-Year P/S Range
Min: 0  Med: 209.50 Max: 1365.34
Current: 1365.34
0
1365.34
Current Ratio 2.96
CYTR's Current Ratio is ranked lower than
62% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. CYTR: 2.96 )
Ranked among companies with meaningful Current Ratio only.
CYTR' s 10-Year Current Ratio Range
Min: 1.04  Med: 4.56 Max: 30
Current: 2.96
1.04
30
Quick Ratio 2.96
CYTR's Quick Ratio is ranked lower than
59% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CYTR: 2.96 )
Ranked among companies with meaningful Quick Ratio only.
CYTR' s 10-Year Quick Ratio Range
Min: 1.04  Med: 4.56 Max: 30
Current: 2.96
1.04
30
Days Sales Outstanding 18.00
CYTR's Days Sales Outstanding is ranked higher than
85% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CYTR: 18.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTR' s 10-Year Days Sales Outstanding Range
Min: 2.32  Med: 57.36 Max: 7752.6
Current: 18
2.32
7752.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.08
CYTR's Price/Net Cash is ranked higher than
72% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CYTR: 4.08 )
Ranked among companies with meaningful Price/Net Cash only.
CYTR' s 10-Year Price/Net Cash Range
Min: 0.55  Med: 5.36 Max: 458
Current: 4.08
0.55
458
Price/Net Current Asset Value 3.45
CYTR's Price/Net Current Asset Value is ranked higher than
76% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. CYTR: 3.45 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYTR' s 10-Year Price/Net Current Asset Value Range
Min: 0.43  Med: 4.11 Max: 108.89
Current: 3.45
0.43
108.89
Price/Tangible Book 3.22
CYTR's Price/Tangible Book is ranked higher than
68% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. CYTR: 3.22 )
Ranked among companies with meaningful Price/Tangible Book only.
CYTR' s 10-Year Price/Tangible Book Range
Min: 0.34  Med: 3.09 Max: 65.43
Current: 3.22
0.34
65.43
Earnings Yield (Greenblatt) (%) -51.54
CYTR's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. CYTR: -51.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYTR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -97  Med: 2011.20 Max: 3114.3
Current: -51.54
-97
3114.3

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 16 84
EPS($) -0.98 -0.88 -0.82 -0.79
EPS without NRI($) -0.98 -0.88 -0.82 -0.79

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CX5N.Germany,
CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.
» More Articles for CYTR

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CytRx Announces the Presentation of its Phase 2b Clinical Trial Design in Small Cell Lung Cancer at... Sep 03 2015
CytRx Announces the Presentation of its Phase 2b Clinical Trial Design in Small Cell Lung Cancer at... Sep 03 2015
CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th... Sep 01 2015
CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th... Sep 01 2015
CYTRX CORP Financials Aug 06 2015
10-Q for CytRx Corp. Aug 05 2015
CytRx Reports 2015 Second Quarter Financial Results Aug 03 2015
CytRx reports 2Q loss Aug 03 2015
CytRx reports 2Q loss Aug 03 2015
CytRx Reports 2015 Second Quarter Financial Results Aug 03 2015
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 03 2015
CYTRX CORP Files SEC form 10-Q, Quarterly Report Aug 03 2015
CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters'... Jul 24 2015
CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters'... Jul 24 2015
The Biotech Rocket is Running Out of Fuel: Three Stocks to Keep You Soaring - Broad Street Alerts Jul 23 2015
CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Jul 21 2015
CytRx Announces Pricing of Public Offering of 9.1 Million Shares of Common Stock Jul 21 2015
CytRx Announces Pricing of Public Offering of 9.1 Million Shares of Common Stock Jul 21 2015
CytRx Announces Proposed Public Offering of Common Stock Jul 20 2015
CYTRX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK